Bladder Cancer Market: By Type (Transitional Cell Carcinoma, Invasive Bladder Cancer), by Treatment (Chemotherapy, Radiation Therapy, Immunotherapy), by Diagnosis (Urine Lab Tests, Imaging Test), by End-User (Hospital, Clinic) - Global Forecast to 2023
ID: MRFR/Pharma/1367-HCR | February 2021 | Region: Global | 85 pages
Market Scenario
The bladder is an organ present in the lower abdomen region near the pelvis. The main function of the bladder is temporary storage of the urine drained from the kidneys. The tube that connects and transfers the urine from the kidney to the bladder is known as ureters. Bladder cancer is one of the most frequently diagnosed cancers and is ranked 9th as per the prevalence rate. This condition is more prevalent in men as compared to women, yet it varies in different countries.
Bladder cancer is known to be a urologic malignancy that occurs in the tissues of the urinary bladder. It is generally characterized by the uncontrolled division of cells arising from the epithelial lining and may proliferate to the muscular wall of the urinary bladder. The exact causes of bladder cancer are still unknown.
Conversely, some of the risk factors include chronic bladder infection, continuous exposure to radiation, tobacco consumption, and excessive smoking. This condition can affect any age group. However, it is more prevalent in adults aged over 50 years. Moreover, the witnessed global trends show that smoking tobacco is the most prevalent cause of bladder cancer.
The increasing bladder cancer cases, technological developments, drug innovations about the bladder cancer, government initiatives, rise in aging population, advanced health care services, the upsurge in awareness about bladder diseases and their available therapies in the market, and increasing health care expenditure are likely to drive the bladder cancer market globally.
However, the rise in the number of drug patent expirations, the rise in the use of generic drugs, asymptomatic nature of the disease, high costs of therapies, and inaccurate and unaffordable diagnosis may restrain the growth of the market. Moreover, factors such as increasing awareness about bladder cancer, progressive health care services with growing health care expenditure, acceptance of effective diagnostic tools, and rising influence of targeted biologics are expected to propel the global bladder cancer market.
The global market for bladder cancer is expected to grow at a CAGR of approximately 12.5% during the forecast period, 2017–2023.
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
Intended Audience
- Bladder cancer drug companies
- Suppliers and distributors of drugs
- Healthcare service providers
- Research and consulting firms
- Medical research institutes
- Venture capitalists
- Community centers
Segmentation
The global bladder cancer market is segmented on the basis of type, treatment, diagnosis, and end-user.
On the basis of type, the global bladder cancer market is segmented into transitional cell bladder cancer, invasive bladder cancer, superficial bladder cancer, squamous cell bladder cancer, adenocarcinoma, and others.
On the basis of treatment, the global bladder cancer market is classified into chemotherapy, immunotherapy, radiation therapy, surgery, and others. Chemotherapy is classified into Valstar (valrubicin), Javlor (vinflunine ditartrate), Mitomycin C, Gemcitabine and cisplatin chemotherapy (GemCis), and others.
On the basis of diagnosis, the global bladder cancer market is classified into urine lab tests, cystoscopy, biopsy, imaging tests, and others. The urine lab tests are classified into urinalysis, urine cytology, urine culture, and urine tumor marker test. The imaging test is further divided into Intravenous Pyelogram (IVP), Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI) scan, and bladder ultrasound.
On the basis of end-user, the global bladder cancer market is classified into, hospitals, clinics, cancer care centers, and others.
Regional Analysis
The global bladder cancer market consists of four regions, namely, America, Europe, Asia Pacific, and the Middle East and Africa.
Americas dominated the global bladder cancer market owing to the increase in the occurrence of bladder cancer, innovative healthcare solutions, advanced health care infrastructure, and increasing concern about bladder problems. Although, the bladder cancer market in the U.S. is growing at a slow pace than other regions, this country will continue to dominate the market over the forecast period due to factors such as the growing focus of vendors to develop targeted therapies and the presence of major vendors such as Merck & Co. Inc. and Pfizer Inc.
Europe accounts for the second largest share of the market due to the availability of better healthcare solutions and rise in bladder cancer cases in the region. The Asia Pacific bladder cancer market is predicted to expand at a high growth rate due to the growing awareness about bladder diseases and innovative diagnostic and treatment options. Major players are investing in the developing countries in Asia as it is considered to be a lucrative market for bladder cancer, thus leading to market growth.
Key Players
Some major players in the global bladder cancer market include AstraZeneca Plc. (U.K.), Bristol-Myers Squibb Company (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline Plc. (U.S.), Novartis International AG (Switzerland), Pfizer Inc. (U.S.), Sanofi S.A. (France), Merck & Co. Inc. (U.S.), Accord Healthcare (U.S.), Bedford Lab (U.S.), and others.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Bladder cancer Market, by Type
6.1 Introduction
6.2 Transitional Cell Carcinoma
6.2.1 Market Estimates & Forecast, 2017 – 2023
6.3 Invasive Bladder Cancer
6.3.1 Market Estimates & Forecast, 2017 – 2023
6.4 Superficial Bladder Cancer
6.4.1 Market Estimates & Forecast, 2017 – 2023
6.5 Adenocarcinomax
6.5.1 Market Estimates & Forecast, 2017 – 2023
6.6 Other rare types
Chapter 7. Global Bladder Cancer Market, by Treatment
7.1 Introduction
7.2 Chemotherapy
7.2.1 Market Estimates & Forecast, 2017 – 2023
7.2.2 Valstar (valrubicin)
7.2.2.1 Market Estimates & Forecast, 2017 – 2023
7.2.3 Javlor (vinflunine ditartrate),
7.2.3.1 Market Estimates & Forecast, 2017 – 2023
7.2.4 Mitomycin C
7.2.4.1 Market Estimates & Forecast, 2017 – 2023
7.2.5 Gemcitabine and cisplatin chemotherapy (GemCis)
7.2.5.1 Market Estimates & Forecast, 2017 – 2023
7.2.6 Others
7.3 Radiation Therapy
7.3.1 Market Estimates & Forecast, 2017 – 2023
7.4 Immunotherapy
7.4.1 Market Estimates & Forecast, 2017 – 2023
7.5 Radical Cystectomy
7.5.1 Market Estimates & Forecast, 2017 – 2023
7.6 Other
Chapter 8. Global Bladder Cancer Market, by Diagnosis
8.1 Introduction
8.2 Urine Lab Tests
8.2.1 Market Estimates & Forecast, 2017 – 2023
8.2.2 Urinalysis
8.2.2.1 Market Estimates & Forecast, 2017 – 2023
8.2.3 Urine Cytology
8.2.3.1 Market Estimates & Forecast, 2017 – 2023
8.2.4 Urine Culture
8.2.4.1 Market Estimates & Forecast, 2017 – 2023
8.2.5 Urine Tumor Marker Test
8.2.5.1 Market Estimates & Forecast, 2017 – 2023
8.3 Cystoscopy
8.3.1 Market Estimates & Forecast, 2017 – 2023
8.4 Biopsy
8.4.1 Market Estimates & Forecast, 2017 – 2023
8.4 Imaging Test
8.4.1 Market Estimates & Forecast, 2017 – 2023
8.4.2 Intravenous Pyelogram (IVP)
8.4.2.1 Market Estimates & Forecast, 2017 – 2023
8.4.3 Computed Tomography (CT) scan
8.4.3.1 Market Estimates & Forecast, 2017 – 2023
8.4.4 Magnetic Resonance Imaging (MRI) Scan
8.4.4.1 Market Estimates & Forecast, 2017 – 2023
8.4.5 Bladder Ultrasound
8.4.5.1 Market Estimates & Forecast, 2017 – 2023
8.5 Other
Chapter 9. Global Bladder Cancer Market, by End Users
9.1 Introduction
9.2 Hospital
9.2.1 Market Estimates & Forecast, 2017 – 2023
9.3 Clinic
9.3.1 Market Estimates & Forecast, 2017 – 2023
9.4 Cancer Care Centers
9.4.1 Market Estimates & Forecast, 2017 – 2023
9.5 Other
Chapter .8 Global Bladder Cancer Market, by Region
8.1 Introduction
8.2 Americas
8.2.1 North America
8.2.1.1 U.S.
8.2.1.2 Canada
8.2.2 South America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.4 Spain
8.3.1.5 U.K
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Republic of Korea
8.4.6 Rest of Asia Pacific
8.5 The Middle East & Africa
8.5.1 United Arab Emirates
8.5.2 Saudi Arabia
8.5.3 Oman
8.5.4 Kuwait
8.5.5 Qatar
8.5.6 Rest of the Middle East & Africa
Chapter 9 Company Landscape
9.1 Introduction
9.2 Market Share Analysis
9.3 Key Development & Strategies
9.3.1 Key Developments
Chapter 10 Company Profiles
10.1 AstraZeneca plc.
10.1.1 Company Overview
10.1.2 Product Overview
10.1.3 Financials
10.1.4 SWOT Analysis
10.2 Bristol-Myers Squibb Company
10.2.1 Company Overview
10.2.2 Product Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Celgene Corporation.
10.3.1 Company Overview
10.3.2 Product Overview
10.3.3 Financial Overview
10.3.4 Key Development
10.3.5 SWOT Analysis
10.4 Eli Lilly and Company.
10.4.1 Company Overview
10.4.2 Product/Business Segment Overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis
10.5 F. Hoffmann-La Roche AG
10.5.1 Company Overview
10.5.2 Product Overview
10.5.3 Financial overview
10.5.4 Key Developments
10.6 GlaxoSmithKline plc.
10.6.1 Company Overview
10.6.2 Product Overview
10.6.3 Financial Overview
10.6.4 Key Developments
10.7 Novartis International AG
10.7.1 Overview
10.7.2 Product Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Pfizer Inc.
10.8.1 Company Overview
10.8.2 Product/Business Segment Overview
10.8.3 Financial Overview
10.8.4 Key Development
10.8.5 SWOT Analysis
10.9 Swastika international Co.
10.9.1 Company Overview
10.9.2 Product Overview
10.9.3 Financial overview
10.9.4 Key Developments
10.10 Stanley Black & Decker
10.10.1 Company Overview
10.10.2 Product Overview
10.10.3 Financial overview
10.10.4 Key Developments
10.11 Celgene Corporation.
10.11.1 Company Overview
10.11.2 Product Overview
10.11.3 Financial overview
10.11.4 Key Developments
10.12 Others
Chapter 11 MRFR Conclusion
11.1 Key Findings
11.1.1 From CEO’s View Point
11.1.2 Unmet Needs of the Market
11.2 Key Companies to Watch
11.3 Prediction of Pharmaceutical industry
Chapter 12 Appendix
LIST OF TABLES
Table 1 Bladder cancer Industry Synopsis, 2017 – 2023
Table 2 Bladder cancer Market Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Bladder cancer Market by Region, 2017 – 2023, (USD Million)
Table 4 Bladder cancer Market by Type, 2017 – 2023, (USD Million)
Table 5 Bladder cancer Market by Treatment, 2017 – 2023, (USD Million)
Table 6 Bladder cancer Market by Diagnosis, 2017 – 2023, (USD Million)
Table 7 Bladder cancer Market by End Users, 2017 – 2023, (USD Million)
Table 8 North America Bladder cancer Market by Type, 2017 – 2023, (USD Million)
Table 9 North America Bladder cancer Market by Treatment, 2017 – 2023, (USD Million)
Table 10 North America Bladder cancer Market by Diagnosis, 2017 – 2023, (USD Million)
Table 11 North America Bladder cancer Market by End User, 2017 – 2023, (USD Million)
Table 12 US Bladder cancer Market by Type, 2017 – 2023, (USD Million)
Table 13 US Bladder cancer Market by Treatment, 2017 – 2023, (USD Million)
Table 14 US Bladder cancer Market by Diagnosis, 2017 – 2023, (USD Million)
Table 15 US Bladder cancer Market by End User, 2017 – 2023, (USD Million)
Table 16 Canada Bladder cancer Market by Type, 2017 – 2023, (USD Million)
Table 17 Canada Bladder cancer Market by Treatment, 2017 – 2023, (USD Million)
Table 18 Canada Bladder cancer Market by Diagnosis, 2017 – 2023, (USD Million)
Table 19 Canada Bladder cancer Market by End User, 2017 – 2023, (USD Million)
Table 20 South America Bladder cancer Market by Type, 2017 – 2023, (USD Million)
Table 21 South America Bladder cancer Market by Treatment, 2017 – 2023, (USD Million)
Table 22 South America Bladder cancer Market by Diagnosis, 2017 – 2023, (USD Million)
Table 23 South America Bladder cancer Market by End User, 2017 – 2023, (USD Million)
Table 24 Europe Bladder cancer Market by Type, 2017 – 2023, (USD Million)
Table 25 Europe Bladder cancer Market by Treatment, 2017 – 2023, (USD Million)
Table 26 Europe Bladder cancer Market by Diagnosis, 2017 – 2023, (USD Million)
Table 27 Europe Bladder cancer Market by End User, 2017 – 2023, (USD Million)
Table 28 Western Europe Bladder cancer Market by Type, 2017 – 2023, (USD Million)
Table 29 Western Europe Bladder cancer Market by Treatment, 2017 – 2023, (USD Million)
Table 30 Western Europe Bladder cancer Market by Diagnosis, 2017 – 2023, (USD Million)
Table 31 Western Europe Bladder cancer Market by End User, 2017 – 2023, (USD Million)
Table 32 Eastern Europe Bladder cancer Market by Type, 2017 – 2023, (USD Million)
Table 33 Eastern Europe Bladder cancer Market by Treatment, 2017 – 2023, (USD Million)
Table 34 Eastern Europe Bladder cancer Market by Diagnosis, 2017 – 2023, (USD Million)
Table 35 Eastern Europe Bladder cancer Market by End User, 2017 – 2023, (USD Million)
Table 36 Asia Pacific Bladder cancer Market by Type, 2017 – 2023, (USD Million)
Table 37 Asia Pacific Bladder cancer Market by Treatment, 2017 – 2023, (USD Million)
Table 38 Asia Pacific Bladder cancer Market by Diagnosis, 2017 – 2023, (USD Million)
Table 39 Asia Pacific Bladder cancer Market by End User, 2017 – 2023, (USD Million)
Table 40 The Middle East & Africa Bladder cancer Market by Type, 2017 – 2023, (USD Million)
Table 41 The Middle East & Africa Bladder cancer Market by Treatment, 2017 – 2023, (USD Million)
Table 42 The Middle East & Africa Bladder cancer Market by Diagnosis, 2017 – 2023, (USD Million)
Table 43 The Middle East & Africa Bladder cancer Market by End User, 2017 – 2023, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Bladder cancer Market
Figure 3 Segmentation Market Dynamics for Bladder cancer Market
Figure 4 Global Bladder cancer Market Share, by Type 2016
Figure 5 Global Bladder cancer Market Share, by Treatment 2016
Figure 6 Global Bladder cancer Market Share, by Diagnosis 2016
Figure 7 Global Bladder cancer Market Share, by End-User 2016
Figure 8 Global Bladder cancer Market Share, by Region, 2016
Figure 9 Americas Bladder cancer Market Share, by Country, 2016
Figure 10 Europe Bladder cancer Market Share, by Country, 2016
Figure 11 Asia Pacific Bladder cancer Market Share, by Country, 2016
Figure 12 Middle East & Africa Bladder cancer Market Share, by Country, 2016
Figure 13 Global Bladder cancer Market: Company Share Analysis, 2016 (%)
Figure 14 AstraZeneca plc: Key Financials
Figure 15 AstraZeneca plc: Segmental Revenue
Figure 16 AstraZeneca plc: Geographical Revenue
Figure 17 Bristol-Myers Squibb Company: Key Financials
Figure 18 Bristol-Myers Squibb Company: Segmental Revenue
Figure 19 Bristol-Myers Squibb Company: Geographical Revenue
Figure 20 Celgene Corporation.: Key Financials
Figure 21 Celgene Corporation.: Segmental Revenue
Figure 22 Celgene Corporation.: Geographical Revenue
Figure 23 Eli Lilly and Company: Key Financials
Figure 24 Eli Lilly and Company: Segmental Revenue
Figure 25 Eli Lilly and Company: Geographical Revenue
Figure 26 F. Hoffmann-La Roche AG: Key Financials
Figure 27 F. Hoffmann-La Roche AG: Segmental Revenue
Figure 28 F. Hoffmann-La Roche AG: Geographical Revenue
Figure 29 GlaxoSmithKline plc: Key Financials
Figure 30 GlaxoSmithKline plc: Segmental Revenue
Figure 31 GlaxoSmithKline plc: Geographical Revenue
Figure 32 Novartis International AG: Key Financials
Figure 33 Novartis International AG: Segmental Revenue
Figure 34 Novartis International AG: Geographical Revenue
Figure 35 Pfizer Inc.: Key Financials
Figure 36 Pfizer Inc.: Segmental Revenue
Figure 37 Pfizer Inc.: Geographical Revenue
